High-yield points
- Where and how often: at the foramen of Monro; found in 10–25% of TSC; more common with TSC2; median diagnosis at 8 years, but adults grow them too .
- Acute hydrocephalus means surgery or CSF diversion.
- Asymptomatic growth: everolimus is first-line for many. It gave a 50% or greater reduction in 35% at about 10 months and in 49% over the extension .
- mTOR inhibitors must be continued: SEGAs regrow when they are stopped or underdosed .
- LITT is an emerging middle path. In Dr. Hauptman's series, volume fell about 49% with few complications .
- Every SEGA patient needs lifelong imaging surveillance.
Landmark papers
- Krueger et al., N Engl J Med 2010: a prospective open-label phase 1/2 trial of everolimus for growing SEGA (28 patients). Volume fell by 30% or more in 75% at 6 months, and no one needed surgery .
- EXIST-1 (Franz et al., Lancet 2013): a phase 3 randomized trial (117 patients). A 50% or greater SEGA reduction occurred in 35% with everolimus vs 0% with placebo .
In tuberous sclerosis complex (TSC), SEGA is the commonest CNS tumor. It is benign, but because it sits at the foramen of Monro it can cause obstructive hydrocephalus, which can be fatal .
The field has moved from "resect everything that grows" to a choice between three modalities:
- open surgery;
- mTOR inhibitors;
- laser interstitial thermal therapy (LITT) .
Definition and natural history
- How common :
- SEGAs occur in 10–20% of people with TSC by consensus estimates.
- The TOSCA registry found 25% (554 of 2,216) .
- Location: arises near the foramen of Monro, and growth eventually occludes it .
- SEGA vs subependymal nodule: a SEGA is distinguished by size (typically 1 cm or more) and documented growth.
- EXIST-1 enrolled lesions of 1 cm or more with serial growth, a new lesion of 1 cm or more, or new or worsening hydrocephalus .
- Age (TOSCA) :
- median age at diagnosis 8 years, but 18.1% were diagnosed after 18;
- growth occurred in 22.7% of patients aged 18 or under and 11.6% of adults.
- Genotype: more common with TSC2 than TSC1 (33.7% vs 13.2%) .
- Symptoms (42.1% of patients with SEGA) :
- raised intracranial pressure;
- increased seizure frequency (15.8%);
- behavioral disturbance (11.9%);
- cognitive regression (9.9%).
Screening
- Serial brain MRI through childhood and young adulthood, in line with the international surveillance recommendations .
- Watch for: ventricular enlargement and lesion growth.
- Families should know the symptoms of hydrocephalus: headache, vomiting, lethargy, and behavioral or seizure change.
Choosing treatment
- Consensus: both mTOR inhibitors and surgery have a role, and particular SEGA-related situations favor one or the other .
- Practice (TOSCA): surgery was used in 59.6% and mTOR inhibitors in 49% of treated patients .
- Favor surgery (open or endoscopic):
- acute symptomatic hydrocephalus or raised ICP;
- a large or rapidly growing tumor causing mass effect;
- a well-circumscribed lesion that can be removed completely;
- poor tolerance of, adherence to or access to mTOR inhibitors.
- Favor an mTOR inhibitor:
- asymptomatic or slowly growing SEGA;
- bilateral SEGAs, or a high-risk surgical location;
- additional systemic TSC targets (angiomyolipoma, seizures, skin);
- high anesthetic or surgical risk.
- Consider LITT :
- a small to moderate SEGA without acute hydrocephalus;
- a patient who is not a candidate for, or not tolerating, mTOR inhibitors.
mTOR inhibitors (everolimus, sirolimus)
- Phase 1/2 trial (Krueger 2010) : 28 patients aged 3 or older with growing SEGA.
- The primary SEGA shrank by 30% or more in 75% and by 50% or more in 32% at 6 months.
- Reductions were seen within 3 months.
- No patient needed surgery or developed new hydrocephalus.
- EXIST-1 (phase 3) :
- Design: 117 patients, everolimus vs placebo (2:1), titrated to a trough of 5–15 ng/mL.
- Result: 35% had 50% or more SEGA volume reduction, vs 0% on placebo.
- Side effects: mostly grade 1–2. The commonest were mouth ulceration (32%) and stomatitis (31%).
- EXIST-1 extension :
- median exposure 29.3 months;
- 49% reached a 50% or greater reduction;
- treatment-related grade 3–4 events in 32%, most often stomatitis and pneumonia;
- 5% withdrew for adverse events.
- Durability depends on continuing the drug.
- Regrowth after discontinuation suggests everolimus must be given indefinitely to keep SEGAs suppressed .
- In a dose-weaning series, halving the sirolimus dose let SEGAs regrow by 84% and 32%. Doses under 2.5 mg/m² did not maintain response .
- Practical points:
- trough monitoring;
- mouth care for stomatitis;
- infection vigilance;
- cost;
- long-term adherence.
- In Dr. Hauptman's group's series, 4 patients reduced or stopped mTOR inhibitors because of cost or side effects .
Open and endoscopic surgery
- Historically the mainstay. It can carry significant morbidity .
- Approaches: chosen by size, ventricular size and extension:
- transcallosal or transcortical-transventricular;
- endoscopic resection for selected smaller lesions.
- Watch for:
- fornix and deep venous injury;
- postoperative intraventricular hemorrhage;
- persistent hydrocephalus.
- Plan CSF diversion when hydrocephalus does not resolve with tumor removal.
- Complete resection is usually curative locally, but new SEGAs can still arise from other subependymal nodules. Surveillance continues for life.
Laser interstitial thermal therapy
- Technical reports: two pediatric SEGAs shrank after LITT .
- Dr. Hauptman's group compared all three modalities (Boop et al., 2023): a single-institution retrospective study, 2010–2021 .
- Groups: 4 LITT (3 LITT alone), 3 open resection, 4 mTOR inhibitor alone.
- Mean tumor volume reduction:
- LITT 48.6 ± 13.8%;
- open resection 90.7 ± 39.8%;
- mTOR inhibitors 67.1 ± 17.2%.
- Differences between groups were not significant (p = 0.0513), and follow-up duration did not differ.
- Complications: only 1 patient needed permanent CSF diversion.
- Conclusion: LITT was effective with very few complications and is less invasive than open resection.
- It may suit patients who are not mTOR inhibitor candidates.
- The authors proposed an updated SEGA paradigm that includes LITT in selected cases .
- Limits:
- LITT does not relieve acute obstruction, so CSF diversion may still be needed;
- post-ablation swelling near the foramen of Monro must be anticipated;
- the evidence is small series only.
- Background: Dr. Hauptman reviewed the bench-to-bedside path of everolimus for SEGA soon after the first trial .
Related topics
- Tuberous Sclerosis Complex: the underlying disorder and systemic surveillance.
- Drug-Resistant Epilepsy in TSC: seizure management in the same patients.
- LITT in Epilepsy Surgery: laser ablation technique.
References
- Boop S, Bonda D, Randle S, et al. A comparison of clinical outcomes for subependymal giant cell astrocytomas treated with laser interstitial thermal therapy, open surgical resection, and mTOR inhibitors. Pediatr Neurosurg 2023;58(3):150–159. doi:10.1159/000531210. PMID 37232001. verified
- Northrup H, Aronow ME, Bebin EM, et al. Updated international tuberous sclerosis complex diagnostic criteria and surveillance and management recommendations. Pediatr Neurol 2021;123:50–66. doi:10.1016/j.pediatrneurol.2021.07.011. PMID 34399110. verified
- Krueger DA, Care MM, Holland K, et al. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010;363(19):1801–1811. doi:10.1056/NEJMoa1001671. PMID 21047224. verified
- Roth J, Roach ES, Bartels U, et al. Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012. Pediatr Neurol 2013;49(6):439–444. doi:10.1016/j.pediatrneurol.2013.08.017. PMID 24138953. verified
- Jansen AC, Belousova E, Benedik MP, et al. Clinical characteristics of subependymal giant cell astrocytoma in tuberous sclerosis complex. Front Neurol 2019;10:705. doi:10.3389/fneur.2019.00705. PMID 31333563. verified
- Franz DN, Belousova E, Sparagana S, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 2013;381(9861):125–132. doi:10.1016/S0140-6736(12)61134-961134-9). PMID 23158522. verified
- Dadey DY, Kamath AA, Leuthardt EC, et al. Laser interstitial thermal therapy for subependymal giant cell astrocytoma: technical case report. Neurosurg Focus 2016;41(4):E9. doi:10.3171/2016.7.FOCUS16231. PMID 27690646. verified
- Franz DN, Belousova E, Sparagana S, et al. Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study. Lancet Oncol 2014;15(13):1513–1520. doi:10.1016/S1470-2045(14)70489-970489-9). PMID 25456370. verified
- Tran LH, Zupanc ML. Long-term everolimus treatment in individuals with tuberous sclerosis complex: a review of the current literature. Pediatr Neurol 2015;53(1):23–30. doi:10.1016/j.pediatrneurol.2014.10.024. PMID 26092412. verified
- Weidman DR, Pole JD, Bouffet E, et al. Dose-level response rates of mTor inhibition in tuberous sclerosis complex (TSC) related subependymal giant cell astrocytoma (SEGA). Pediatr Blood Cancer 2015;62(10):1754–1760. doi:10.1002/pbc.25573. PMID 25929843. verified
- Hauptman JS. From the bench to the bedside: everolimus for subependymal giant cell astrocytomas in tuberous sclerosis complex, optic nerve regeneration, targeted cytotoxins for gliomas. Surg Neurol Int 2011;2:2. doi:10.4103/2152-7806.75587. PMID 21297924. verified
Verification (2026-11-17):
- Each reference's authors, title, journal, year, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
- Reference 11 has no PubMed abstract and is cited only as a review.
Caveats:
- The following are standard practice, not drawn from the cited abstracts:
- the lists of factors favoring surgery, mTOR inhibitors or LITT, which synthesize reference 4's statement that SEGA-related conditions favor certain treatments;
- surgical approaches and risks, and complete resection as definitive;
- mouth care and trough monitoring;
- new SEGAs arising after resection;
- LITT's limits.
- The 1 cm size threshold comes from the EXIST-1 eligibility criteria; formal definitions vary.
- Reference 1 is a small series (3–4 patients per group), and its comparison was not powered.
- The figure is an original schematic.